This may be explained by the fact that, compared to those with metastatic cancer, most individuals with localized PC survive longer after diagnosis and die not from PC, and other factors may have a stronger impact on their mortality than HSD3B1 (1245C). This evidence concerns the gene HSD3B1 and pachyonychia congenita.